These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 9070519)

  • 1. Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.
    Eriksson BI; Ekman S; Lindbratt S; Baur M; Bach D; Torholm C; Kälebo P; Close P
    J Bone Joint Surg Am; 1997 Mar; 79(3):326-33. PubMed ID: 9070519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.
    Eriksson BI; Wille-Jørgensen P; Kälebo P; Mouret P; Rosencher N; Bösch P; Baur M; Ekman S; Bach D; Lindbratt S; Close P
    N Engl J Med; 1997 Nov; 337(19):1329-35. PubMed ID: 9358126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of deep-vein thrombosis after total hip replacement: direct thrombin inhibition with recombinant hirudin, CGP 39393.
    Eriksson BI; Ekman S; Kalebo P; Zachrisson B; Bach D; Close P
    Lancet; 1996 Mar; 347(9002):635-9. PubMed ID: 8596376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of deep-vein thrombosis and pulmonary embolism after total hip replacement. Comparison of low-molecular-weight heparin and unfractionated heparin.
    Eriksson BI; Kälebo P; Anthymyr BA; Wadenvik H; Tengborn L; Risberg B
    J Bone Joint Surg Am; 1991 Apr; 73(4):484-93. PubMed ID: 2013587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fixed-dose combination of low molecular weight heparin with dihydroergotamine versus adjusted-dose unfractionated heparin in the prevention of deep-vein thrombosis after total hip replacement.
    Horbach T; Wolf H; Michaelis HC; Wagner W; Hoffmann A; Schmidt A; Beck H
    Thromb Haemost; 1996 Feb; 75(2):246-50. PubMed ID: 8815569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. A clinical trial comparing efficacy and safety. Enoxaparin Clinical Trial Group.
    Colwell CW; Spiro TE; Trowbridge AA; Morris BA; Kwaan HC; Blaha JD; Comerota AJ; Skoutakis VA
    J Bone Joint Surg Am; 1994 Jan; 76(1):3-14. PubMed ID: 8288662
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct thrombin inhibition with Rec-hirudin CGP 39393 as prophylaxis of thromboembolic complications after total hip replacement.
    Eriksson BI; Kälebo P; Ekman S; Lindbratt S; Kerry R; Close P
    Thromb Haemost; 1994 Aug; 72(2):227-31. PubMed ID: 7831657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement. A randomized trial. The German Hip Arthroplasty Trial (GHAT) Group.
    Arch Orthop Trauma Surg; 1992; 111(2):110-20. PubMed ID: 1314065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Desirudin (Revasc) to prevent thromboembolic complications after hip or knee replacement surgery].
    Heiz-Valle C; de Maistre E; Commun N; Heck M; Lecompte T; Hoffman M
    Therapie; 2002; 57(1):34-8. PubMed ID: 12090145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Economic evaluation of desirudin vs heparin in deep vein thrombosis prevention after hip replacement surgery.
    Levin LA; Horst M; Bergqvist D
    Pharmacoeconomics; 1998 Jan; 13(1 Pt 2):111-8. PubMed ID: 10176145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Desirudin: a review of its use in the management of thrombotic disorders.
    Matheson AJ; Goa KL
    Drugs; 2000 Sep; 60(3):679-700. PubMed ID: 11030473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin.
    Levine MN; Hirsh J; Gent M; Turpie AG; Leclerc J; Powers PJ; Jay RM; Neemeh J
    Ann Intern Med; 1991 Apr; 114(7):545-51. PubMed ID: 1848054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin.
    Leyvraz PF; Bachmann F; Hoek J; Büller HR; Postel M; Samama M; Vandenbroek MD
    BMJ; 1991 Sep; 303(6802):543-8. PubMed ID: 1655136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment. ENOXACAN Study Group.
    Br J Surg; 1997 Aug; 84(8):1099-103. PubMed ID: 9278651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost effectiveness of desirudin compared with a low molecular weight heparin in the prevention of deep vein thrombosis after total hip replacement surgery.
    Levin LA; Bergqvist D
    Pharmacoeconomics; 2001; 19(5 Pt 2):589-97. PubMed ID: 11465303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin.
    Francis CW; Pellegrini VD; Totterman S; Boyd AD; Marder VJ; Liebert KM; Stulberg BN; Ayers DC; Rosenberg A; Kessler C; Johanson NA
    J Bone Joint Surg Am; 1997 Sep; 79(9):1365-72. PubMed ID: 9314399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. RD Heparin Arthroplasty Group.
    J Bone Joint Surg Am; 1994 Aug; 76(8):1174-85. PubMed ID: 8056798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
    Kakkar VV; Howes J; Sharma V; Kadziola Z
    Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial.
    Kakkar VV; Boeckl O; Boneu B; Bordenave L; Brehm OA; Brücke P; Coccheri S; Cohen AT; Galland F; Haas S; Jarrige J; Koppenhagen K; LeQuerrec A; Parraguette E; Prandoni P; Roder JD; Roos M; Rüschemeyer C; Siewert JR; Vinazzer H; Wenzel E
    World J Surg; 1997 Jan; 21(1):2-8; discussion 8-9. PubMed ID: 8943170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Markers of hemostatic system activation during thromboprophylaxis with recombinant hirudin in total hip replacement.
    Cofrancesco E; Cortellaro M; Leonardi P; Corradi A; Ravasi F; Bertocchi F
    Thromb Haemost; 1996 Mar; 75(3):407-11. PubMed ID: 8701398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.